Company: DRTSW
Filing Date: 2025-06-23
Form Type: F-3
Source: 0001213900-25-056744
Chunk: 17

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-06-23
Form: F-3
Chunk 17
---
 or above the price you paid.

If securities or industry analysts publish negative reports about our business, our share price and trading volume could decline.

The market price for our
ordinary shares depends in part on the research and reports that securities or industry analysts publish about us or our business, our
market and our competitors. We do not have any control over these analysts. If one or more of the analysts who cover us downgrade our
shares or change their opinion of our shares, our share price would likely decline. If one or more of these analysts cease coverage of
our Company or fail to regularly publish reports on us, we could lose visibility in the financial markets, which could cause our share
price or trading volume to decline.

Sales of a substantial number of our ordinary shares in the public market, or the perception that they may occur, could cause the price of our ordinary shares to fall.

The market price of our ordinary
shares could decline as a result of sales of a large number of our ordinary shares in the public market following this offering. A substantial
majority of our outstanding ordinary shares are freely tradeable without restriction or further registration under the Securities Act
of 1933, as amended (the “Securities Act”). Volatility or a reduction in the market price of our ordinary shares could have
an adverse effect on the market price of the shares and existing warrants. The perception that these sales might occur may also cause
the market price of our ordinary shares to decline.

Because we do not anticipate paying any cash dividends on our ordinary shares in the foreseeable future, capital appreciation, if any, will be your sole source of gain.

We have never declared or
paid cash dividends on our ordinary shares. We anticipate that we will retain our earnings, if any, for future growth and therefore do
not anticipate paying cash dividends in the future. As a result, only appreciation of the price of our ordinary shares will provide a
return to shareholders.

<div align='center'>6</div>

You may experience future dilution as a result of future equity offerings.

In order to raise additional
capital, we expect to in the future offer additional ordinary shares or other securities convertible into or exchangeable for our ordinary
shares. We cannot assure you that we will be able to sell ordinary shares or other securities in any other offering at a price per ordinary
share that is equal to or greater than the price per ordinary share paid by investors in this offering, and investors purchasing ordinary
shares or other securities in the future could have rights superior to